# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-13 (automated monitor)
**Data as of:** clinical_trials_latest.json & pubmed_recent_latest.json generated 2026-07-13 02:05
**Bottom line:** Quiet day. No net change in the clinical-trial universe vs. yesterday; PubMed churned +8/−9 papers with one high-value multi-therapy cross-domain paper. No last-7-day breaking news that isn't already captured in the hub. Gap analysis is 1–3 days old and still valid.

---

## File System Status

All expected pipeline outputs are present and fresh:

| File | Last generated | Age | Status |
|------|----------------|-----|--------|
| clinical_trials_latest.json | 2026-07-13 02:05 | today | Fresh |
| pubmed_recent_latest.json | 2026-07-13 02:05 | today | Fresh |
| literature_gap_report.md | 2026-07-12 09:07 | 1 day | Fresh |
| literature_gap_data.json | 2026-07-10 02:17 | 3 days | OK (re-run this week) |
| hub_monitor_report.md | 2026-07-12 02:10 | 1 day | Fresh |

Daily snapshots for both clinical trials and PubMed exist through 2026-07-13. No missing or stale critical files. (hub_monitor.py itself last flagged 810 legacy result files >14 days old — these are historical daily snapshots and are expected, not a problem.)

**Note on hub_monitor_report.md:** it reflects the 07-11→07-12 scan, so it is one cycle behind this report. Snapshot diffs below were computed directly from the 07-12 and 07-13 JSON files.

---

## Clinical Trial Changes (07-12 → 07-13)

**No change.** Trial set is identical between yesterday and today.

- New trials: **0**
- Removed trials: **0**
- Status changes: **0**
- Newly posted results: **0**

Total tracked: **855 trials** (unchanged). Category counts unchanged: T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 75 · T2D Novel Therapies 147 · Diabetes Technology 237 · Recently Completed w/ Results 318.

### Phase 3 RECRUITING watchlist (48 trials active; key programs)

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT04786262 | Vertex | VX-880 (zimislecel) islet cell therapy, T1D |
| NCT06832410 | Vertex | VX-880 efficacy/safety, T1D |
| NCT07088068 | Sanofi | Teplizumab vs placebo, T1D delay |
| NCT07222137 | Eli Lilly | Baricitinib — delay Stage 3 T1D |
| NCT07222332 | Eli Lilly | Baricitinib — preserve beta-cell function (peds) |
| NCT07076199 | Novo Nordisk | Insulin icodec, T1D |
| NCT07564414 | Novo Nordisk | CagriSema, T2D |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator), T1D adjunct |
| NCT07258394 | Nanjing Medical U | Dimethyl fumarate — preserve islet β-cell function |

Key-org programs not yet recruiting but worth tracking: NCT07282613 (Novo, CagriSema), NCT07613307 / NCT07668336 (Lilly, orforglipron Phase 3), NCT06962280 (Lilly, tirzepatide long-term).

### Recently posted results worth a look (last ~10 days)

- **NCT04255433 (Eli Lilly)** — Tirzepatide vs Dulaglutide, results posted **2026-07-08**. Phase 3, key-org — review for the cross-trial combination map (Tier 1 #3).
- **NCT03263494 (Jaeb Center)** — CGM in teens/young adults w/ T1D, results **2026-07-09**.
- **NCT06340854 (Novo Nordisk)** — switching from daily basal to weekly insulin, results **2026-07-02**.
- **NCT06010004 (Eli Lilly)** — Orforglipron long-term safety, results **2026-06-30**.

---

## PubMed Highlights (07-12 → 07-13)

Corpus: **158 unique papers** across 16 alert domains, 30-day lookback. Net change today: **+8 new / −9 dropped** (rolling window).

### New papers today (8)
- **[42250575]** Retatrutide (GIP/GLP-1/glucagon triple agonist) — efficacy & safety *(Key Therapy: retatrutide)*
- **[42437645]** Variant-specific pharmacophoric shifts in GLP-1 receptor — *GLP-1 Pharmacogenomics + orforglipron* (cross-domain)
- **[42436850]** Reasons for initiation / experience with tirzepatide *(T2D GLP-1 New)*
- **[42436945]** GLP-1 RAs and cardiovascular outcomes *(T2D GLP-1 New)*
- **[42437874]** How low could semaglutide prices fall? Production cost analysis *(T2D GLP-1 New)* — relevant to **Health Equity / affordability**
- **[42436714]**, **[42436968]** — deep-learning imaging models *(Diabetes AI/ML)*
- **[42437753]** m6A modification in retinal ischemia-reperfusion *(Diabetes Complications New)*

### Highest-value cross-domain papers (multi-domain = priority)
- **[42419792]** Comparative effects of obesity drugs — spans **orforglipron + retatrutide + CagriSema** (triple key-therapy overlap; strongest signal today)
- **[42437645]** GLP-1 Pharmacogenomics + orforglipron
- **[42411999]** Residual recipient T cells after HSCT — T1D Stem Cell Cure + T1D Immunotherapy
- **[42332392]** Teplizumab (Tzield) for T1D delay — T1D Immunotherapy + teplizumab
- **[42420766]** Early worsening of diabetic retinopathy after hybrid closed-loop — Closed Loop AP + Complications

### Key-therapy tracker (papers in 30-day window)
dapagliflozin 5 · orforglipron 5 · retatrutide 5 · CagriSema 5 · teplizumab 4 · icodec 3 · baricitinib 2 · **zimislecel 0**. Domain volume is evenly capped (~10/domain), so no domain is anomalously hot or cold this cycle.

---

## Gap Analysis Summary (from literature_gap_report.md, 2026-07-12)

Validation level **BRONZE** per Research Doctrine (single analytical source; needs expert confirmation). Top under-researched intersections (Gap Score 100 = zero/near-zero joint publications):

1. **Beta Cell Regen × Health Equity** (0 joint) — equity of access to regenerative therapies is absent
2. **Insulin Resistance × Islet Transplant** (1 joint) — affects graft survival, barely studied
3. **Islet Transplant × Drug Repurposing** (0 joint) — immunosuppressant repurposing for islet protection unexplored
4. **Islet Transplant × Health Equity** (0 joint) — access equity at select centers absent
5. **Gene Therapy × LADA** (0 joint) — no crossover work despite autoimmune mechanism

**Tier 1 alignment (from RESEARCH_DOCTRINE.md):** These gaps map directly onto three of our Tier 1 areas — **Drug Repurposing Computational Screening (#4)**, **Epidemiological/Health-Equity Analysis (#6)**, and **Literature Synthesis & Gap Analysis (#2)**. Gaps #1, #3, #4 are all actionable computational targets we are positioned to fill. Today's new paper [42437874] (semaglutide affordability) and the recurring Health-Equity gaps reinforce the equity-of-access thread as a live contribution lane.

---

## Breaking News (web check, last 7 days)

No genuinely new (last-7-day) breaking item. The significant 2026 developments surfacing in search are all from **June / ADA 2026** and are already reflected in the hub's trial and PubMed data:

- **Tzield (teplizumab)** pediatric Stage 3 T1D indication — FDA approved **2026-06-12** (PROTECT trial). Already tracked (teplizumab appears in trials NCT07088068 and PubMed [42332392]).
- **Retatrutide** Phase 3 (obesity + T2D, plus OSA / knee-OA benefits) — announced June 2026. Tracked (NCT05929079, NCT06297603; PubMed [42250575], [42419792]).
- **Orforglipron** ACHIEVE-2 superiority vs dapagliflozin — tracked (multiple Lilly Phase 3 NCTs; PubMed hits).
- **First generic dapagliflozin** FDA approval (2026) — worth noting for cost/equity analysis; not in trial tracker (post-approval generic).

No Phase 3 topline, FDA action, or major publication in the **07-06 → 07-13** window that isn't already captured. **[Certain]** on trial/PubMed no-change; **[Likely]** that no material external news was missed (web search is coarse on exact dates).

---

## Recommended Actions

1. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. literature_gap_data.json is 3 days old (07-10); refresh to keep the BRONZE gap set current before any expert-review pass.
2. **Review Phase 3 result posting NCT04255433** (Lilly, Tirzepatide vs Dulaglutide, posted 07-08) — feed into the cross-trial combination map (Tier 1 #3, Clinical Trial Intelligence).
3. **Log cross-domain paper [42419792]** (orforglipron + retatrutide + CagriSema comparative) into the evidence network — triple key-therapy overlap is the strongest literature signal this cycle.
4. **Tag [42437874]** (semaglutide affordability) and Health-Equity gap pairs as inputs to a Tier 1 #6 equity-of-access mini-analysis; this thread is recurring.
5. **No tracker edits required today** — trial universe unchanged (855 trials). Next natural tracker update is when new results post or a Phase 3 status flips.

---
*Generated by the automated Diabetes Hub monitor. Read-only review run — no existing files were modified. Evidence levels noted per Research Doctrine; all gap findings remain BRONZE pending expert confirmation.*
